Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177


Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: multicenter experiences.

Oven Ustaalioglu BB, Unal OU, Turan N, Bilici A, Kaya S, Eren T, Ulas A, Inal A, Berk V, Demirci U, Alici S, Bal O, Benekli M, Gumus M.

Asian Pac J Cancer Prev. 2013;14(11):6287-92.


Prognostic impact of lymphovascular invasion compared with that of visceral pleural invasion in patients with pN0 non-small-cell lung cancer and a tumor diameter of 2 cm or smaller.

Tao H, Hayashi T, Sano F, Takahagi A, Tanaka T, Matsuda E, Okabe K.

J Surg Res. 2013 Nov;185(1):250-4. doi: 10.1016/j.jss.2013.05.104. Epub 2013 Jun 22.


Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China.

Li Z, Yu Y, Lu J, Luo Q, Wu C, Liao M, Zheng Y, Ai X, Gu L, Lu S.

J Thorac Oncol. 2009 Jun;4(6):702-9. doi: 10.1097/JTO.0b013e3181a5269d.


Prognostic value of metastatic N1 lymph node ratio and angiolymphatic invasion in patients with pathologic stage IIA non-small cell lung cancer.

Wu CF, Wu CY, Fu JY, Wang CW, Liu YH, Hsieh MJ, Wu YC.

Medicine (Baltimore). 2014 Oct;93(20):e102. doi: 10.1097/MD.0000000000000102. Erratum in: Medicine (Baltimore). 2016 Jan;95(2):e65b7.


Survival analysis of 220 patients with completely resected stage-II non-small cell lung cancer.

Dai Y, Su XD, Long H, Lin P, Fu JH, Zhang LJ, Wang X, Wen ZS, Zhu ZH, Zhang X, Rong TH.

Chin J Cancer. 2010 May;29(5):538-44.


Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.

Yan D, Wei P, An G, Chen W.

J Cardiothorac Surg. 2013 Jun 10;8:149. doi: 10.1186/1749-8090-8-149.


[Two patterns of mediastinal lymph node resection for non-small cell lung cancer of stage IIIA: survival analysis of 219 cases].

Zhang GQ, Han F, Gao SL, A DL, Pang ZL.

Ai Zheng. 2007 May;26(5):519-23. Chinese.


Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy.

Higgins KA, Chino JP, Ready N, D'Amico TA, Berry MF, Sporn T, Boyd J, Kelsey CR.

J Thorac Oncol. 2012 Jul;7(7):1141-7. doi: 10.1097/JTO.0b013e3182519a42.


Prognostic impact and initial recurrence site of lymphovascular and visceral pleural invasion in surgically resected stage I non-small-cell lung carcinoma.

Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G.

Eur J Cardiothorac Surg. 2013 Sep;44(3):e200-6. doi: 10.1093/ejcts/ezt309. Epub 2013 Jun 13.


Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer.

Park SY, Lee JG, Kim J, Byun GE, Bae MK, Lee CY, Kim DJ, Chung KY.

J Cardiothorac Surg. 2013 Jun 11;8:151. doi: 10.1186/1749-8090-8-151.


[Factors influencing survival and recurrence and potential significance of postoperative radiotherapy and adjuvant chemotherapy for stage ⅢA-N2 non-small cell lung cancer].

Han W, Song YZ, He M, Li J, Zhang R, Qiao XY.

Zhonghua Zhong Liu Za Zhi. 2016 Nov 23;38(11):861-867. doi: 10.3760/cma.j.issn.0253-3766.2016.11.012. Chinese.


Prognostic Impact of Multiple Clinicopathologic Risk Factors and c-MET Overexpression in Patients Who Have Undergone Resection of Stage IB Non-Small-Cell Lung Cancer.

Kim IH, Lee IH, Lee JE, Hong SH, Kim TJ, Lee KY, Kim YK, Kim SJ, Sung SW, Park JK, Yoo IR, Kim YS, Kim JO, Kang JH.

Clin Lung Cancer. 2016 Sep;17(5):e31-e43. doi: 10.1016/j.cllc.2016.01.005. Epub 2016 Feb 2.


[Prognostic analysis of curative surgery for stage IIIA-N2 non-small cell lung cancer].

Liu JW, Li J, Lin G, Shang XQ.

Zhonghua Zhong Liu Za Zhi. 2013 Jan;35(1):50-3. doi: 10.3760/cma.j.issn.0253-3766.2013.01.011. Chinese.


Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer.

Koike T, Koike T, Yoshiya K, Tsuchida M, Toyabe S.

J Thorac Cardiovasc Surg. 2013 Aug;146(2):372-8. doi: 10.1016/j.jtcvs.2013.02.057.


Extracapsular extension is a powerful prognostic factor in stage IIA-IIIA non-small cell lung cancer patients with completely resection.

Liu W, Shao Y, Guan B, Hao J, Cheng X, Ji K, Wang K.

Int J Clin Exp Pathol. 2015 Sep 1;8(9):11268-77. eCollection 2015.


Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer.

Ou SH, Zell JA.

J Thorac Oncol. 2008 Aug;3(8):880-6. doi: 10.1097/JTO.0b013e31817dfced.


Radical systematic mediastinal lymphadenectomy versus mediastinal lymph node sampling in patients with clinical stage IA and pathological stage T1 non-small cell lung cancer.

Ma K, Chang D, He B, Gong M, Tian F, Hu X, Ji Z, Wang T.

J Cancer Res Clin Oncol. 2008 Dec;134(12):1289-95. doi: 10.1007/s00432-008-0421-3. Epub 2008 May 27.


Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.

Yoo C, Yoon S, Lee DH, Park SI, Kim DK, Kim YH, Kim HR, Choi SH, Kim WS, Choi CM, Jang SJ, Song SY, Kim SS, Choi EK, Lee JC, Suh C, Lee JS, Kim SW.

Clin Lung Cancer. 2015 Nov;16(6):e203-12. doi: 10.1016/j.cllc.2015.04.004. Epub 2015 Apr 23.


Extent of removal for mediastinal nodal stations for patients with clinical stage I non-small cell lung cancer: effect on outcome.

Jeon HW, Moon MH, Kim KS, Kim YD, Wang YP, Park HJ, Park JK.

Thorac Cardiovasc Surg. 2014 Oct;62(7):599-604. doi: 10.1055/s-0033-1360478. Epub 2014 Jan 13.


Prognostic impact of vascular invasion and standardization of its evaluation in stage I non-small cell lung cancer.

Hamanaka R, Yokose T, Sakuma Y, Tsuboi M, Ito H, Nakayama H, Yamada K, Masuda R, Iwazaki M.

Diagn Pathol. 2015 Apr 2;10:17. doi: 10.1186/s13000-015-0249-5.

Supplemental Content

Support Center